Zevra Therapeutics Stock In The News
| ZVRA Stock | 7.85 0.36 4.38% |
Our overall analysis of Zevra Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Zevra Therapeutics. The specific impact of Zevra Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Zevra Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Zevra Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Zevra Therapeutics Backtesting and Zevra Therapeutics Hype Analysis. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.
Zevra |
Zevra Therapeutics Today Top News and Investor Outlook
Zevra Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Zevra and other traded companies coverage with news coverage. We help investors stay connected with Zevra headlines for the 26th of March to make an informed investment decision based on correlating the impacts of news items on Zevra Stock performance. Please note that trading solely based on the Zevra Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Zevra Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Zevra earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Zevra Therapeutics that are available to investors today. That information is available publicly through Zevra media outlets and privately through word of mouth or via Zevra internal channels. However, regardless of the origin, that massive amount of Zevra data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zevra Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zevra Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zevra Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zevra Therapeutics alpha.
Zevra Largest EPS Surprises
Earnings surprises can significantly impact Zevra Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-03-30 | 2021-12-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-11-10 | 2021-09-30 | -0.07 | -0.05 | 0.02 | 28 | ||
2024-08-13 | 2024-06-30 | -0.43 | -0.48 | -0.05 | 11 | ||
2022-11-09 | 2022-09-30 | -0.13 | -0.19 | -0.06 | 46 | ||
2022-08-11 | 2022-06-30 | -0.12 | -0.19 | -0.07 | 58 | ||
2024-05-08 | 2024-03-31 | -0.48 | -0.4 | 0.08 | 16 |
Zevra Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Zevra Therapeutics Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of March 2025
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView at news.google.com
13th of March 2025
Zevra Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags at finance.yahoo.com
12th of March 2025
Zevra Therapeutics Inc Q4 2024 Earnings Call Highlights Record Revenue and Strategic ... at gurufocus.com
11th of March 2025
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results at gurufocus.com
10th of March 2025
Zevra Therapeutics FY 2024 Earnings Preview at seekingalpha.com
4th of March 2025
Investing in Zevra Therapeutics five years ago would have delivered you a 83 percent gain at finance.yahoo.com
27th of February 2025
Zevra Therapeutics stock rises on 150M asset sale - Investing.com at news.google.com
18th of February 2025
Insider Selling Zevra Therapeutics, Inc. CFO Sells 11,000 Shares of Stock - MarketBeat at news.google.com
14th of February 2025
Disposition of 30544 shares by Neil McFarlane of Zevra Therapeutics at 8.0527 subject to R... at news.google.com
13th of February 2025
Disposition of 61273 shares by Neil McFarlane of Zevra Therapeutics at 7.8571 subject to R... at Neil McFarlane
7th of February 2025
Acquisition by Neil McFarlane of 112500 shares of Zevra Therapeutics subject to Rule 16b-3 at Neil McFarlane
31st of January 2025
Acquisition by Neil McFarlane of 233333 shares of Zevra Therapeutics subject to Rule 16b-3 at Neil McFarlane
8th of January 2025
Zevra Therapeutics Now Covered by Cantor Fitzgerald at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zevra Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zevra Therapeutics' short interest history, or implied volatility extrapolated from Zevra Therapeutics options trading.
Check out Zevra Therapeutics Backtesting and Zevra Therapeutics Hype Analysis. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.